Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Proqr Therapeutics (NQ: PRQR )

1.980 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.980
Bid (Size) 1.830 (1)
Ask (Size) 1.990 (5)
Prev. Close 1.980
Today's Range 1.980 - 1.980
52wk Range 1.110 - 3.290
Shares Outstanding 80,817,079
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024
PRQR stock results show that ProQR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
ProQR Announces Second Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire

Performance

YTD
-4.58%
-4.58%
1 Month
+9.70%
+9.70%
3 Month
+8.20%
+8.20%
6 Month
-1.00%
-1.00%
1 Year
+24.14%
+24.14%

More News

Read More
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces First Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
4 Analysts Have This to Say About ProQR Therapeutics
Via Benzinga
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Year End 2023 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
From ProQR Therapeutics N.V.
Via GlobeNewswire
US Stocks Lower; Dow Falls Over 50 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
ProQR Announces Third Quarter 2023 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Therapeutics Provides Update on Ophthalmic Assets
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Announces Second Quarter 2023 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
From ProQR Therapeutics N.V.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.